Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of treatment outcome with daily high-dose IFN alpha-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy.
Iino S, Tomita E, Kumada H, Suzuki H, Toyota J, Kiyosawa K, Tanikawa K, Sata M, Hayashi N, Kakumu S, Matsushima T, Ohno T. Iino S, et al. Among authors: sata m. Hepatol Res. 2004 Oct;30(2):63-70. doi: 10.1016/j.hepres.2004.07.002. Hepatol Res. 2004. PMID: 15519269
Timing of interferon therapy and sources of infection in patients with acute hepatitis C.
Ogata K, Ide T, Kumashiro R, Kumada H, Yotsuyanagi H, Okita K, Akahane Y, Kaneko S, Tsubouchi H, Tanaka E, Moriwaki H, Nishiguchi S, Kakumu S, Mizokami M, Iino S, Sata M. Ogata K, et al. Among authors: sata m. Hepatol Res. 2006 Jan;34(1):35-40. doi: 10.1016/j.hepres.2005.08.012. Epub 2005 Dec 15. Hepatol Res. 2006. PMID: 16359917
A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan.
Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, Kato J, Iino S, Yotsuyanagi H, Kobayashi Y, Kawamura K, Kakumu S, Kaito M, Ikoma J, Wakusawa S, Okanoue T, Sumida Y, Kimura F, Kajiwara E, Sata M, Ogata K. Yano M, et al. Among authors: sata m. J Gastroenterol. 2004 Jun;39(6):570-4. doi: 10.1007/s00535-003-1344-z. J Gastroenterol. 2004. PMID: 15235875 Clinical Trial.
Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan.
Sugauchi F, Orito E, Ohno T, Tanaka Y, Ozasa A, Kang JH, Toyoda J, Kuramitsu T, Suzuki K, Tanaka E, Akahane Y, Ichida T, Izumi N, Inoue K, Hoshino H, Iino S, Yotsuyanagi H, Kakumu S, Tomita E, Okanoue T, Nishiguchi S, Murawaki Y, Hino K, Onji M, Yatsuhashi H, Sata M, Miyakawa Y, Ueda R, Mizokami M. Sugauchi F, et al. Among authors: sata m. Hepatol Res. 2006 Oct;36(2):107-14. doi: 10.1016/j.hepres.2006.06.001. Epub 2006 Sep 7. Hepatol Res. 2006. PMID: 16956789
Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B.
Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Kobashi H, et al. Among authors: sata m. Hepatol Int. 2009 Jun;3(2):403-10. doi: 10.1007/s12072-008-9108-8. Epub 2008 Dec 9. Hepatol Int. 2009. PMID: 19669367 Free PMC article.
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C.
Kaneko S, Sata M, Ide T, Yamashita T, Hige S, Tomita E, Mochida S, Yamashita Y, Inui Y, Kim SR, Komada N, Mikami T, Satoh S, Morita S, Takaguchi K, Hirashima N, Nishio Y, Watanabe D, Kioka K, Fujiwara K. Kaneko S, et al. Among authors: sata m. Hepatol Res. 2010 Nov;40(11):1072-81. doi: 10.1111/j.1872-034X.2010.00708.x. Epub 2010 Sep 28. Hepatol Res. 2010. PMID: 20880058
1,460 results